The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen
| Authors | |
|---|---|
| Year of publication | 2008 |
| Type | Workshop |
| MU Faculty or unit | |
| Citation | |
| Description | This study is aimed at comparison of ability to overcome the negative prognostic impact of the most common cytogenetic aberrations by treatment regimens based on Velcade or thalidomide. Both new drugs can overcome negative prognostic impact of all named chromosomal abnormalities except gain1q21. However, difference in PFS median between del 17p13 positive and negative patients is not relevant, because of presence of only 1 patient in negative group. The difference in PFS median in gain1q21 positive and negative patients treated by thalidomide based regimen suggests that thalidomide is not able to overcome negative prognostic impact of gain1q21 in contrary of treatment based on Velcade regimen, which probably may overcome poor prognosis of gain1q21. However this findings has to be confirmed on larger cohort of patients with longer follow-up. |
| Related projects: |